Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2020

View Archived Issues

First patient enrolled in phase I study of GEM-103

FDA clears IND for ACE-1702 for the treatment of HER2-expressing solid tumors

Moderna begins phase II study of CMV vaccine mRNA-1647

Nomacopan achieves primary endpoint at interim analysis of phase III CAPSTONE study

Positive results from pivotal phase II study of loncastuximab tesirine in DLBCL

Novel ATX inhibitor shows promise as IOP-lowering therapy in vivo

Daiichi Sankyo presents a new orally potent analgesic, DS-54360155

Mutations in TTC29 gene linked to male infertility

Heptares Therapeutics describes new muscarinic acetylcholine M1 and/or M4 receptor agonists

New tankyrase 1/2 inhibitors patented by Forschungsverbund Berlin and collaborators

Curadev Pharma synthesizes new STING agonists

FGF21 switches sides in pancreatitis

Amyloid after amnesia?

Merck & Co. discovers PCSK9 inhibitors

Treatment effects may spread in LCA gene therapy

New NRTK1 inhibitors disclosed by Beijing Innocare Pharmaceutical Technology

Xuanzhu (Hainan) Biopharmaceutical identifies farnesoid X receptor agonists

Bio-Thera launches adalimumab biosimilar Qletli in China

AKCEA-TTR-LRx begins phase III cardiovascular outcomes study

ContraFect begins dosing in phase III study of exebacase for S. aureus bacteremia

Seelos reports interim phase I data on intranasal racemic ketamine

New REPAIR-MS phase II study begins with CNM-Au8 for MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.